EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Enhanced Fibrinolysis in Lung Cancer Patients: A Functional Assessment Using Lysis Slope Time and Fibrinolytic Biomarkers

Anuha Vellanki, Prakasha Kempaiah iD, Alexander Pohlman, Fakiha Siddiqui, Walter Jeske, Debra Hoppensteadt iD, Jeanine Walenga iD, Jean Amiral iD, W Keith Jones iD, Jawed Fareed iD, Zaid Abdelsattar

Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32

DOI: 10.1177/10760296261475427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 04.08.2026. Verfasst von Anuha Vellanki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pharmacology and Neuroscience, Loyola University Stritch School of Medicine, Maywood, IL, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Fibrinolysis, Fibrin Clot Lysis Time. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Surgery is the cornerstone of treatment for lung cancer. However, cancer and surgery can both independently affect thrombosis and hemostasis with interrelated, but unclear mechanisms. There are currently poor methods of detection and prediction of subsequent complications. In this context, we aim to evaluate levels of fibrinolysis in peri-operative lung cancer patients, via two different approaches, to identify potential biological mechanisms and trends around surgery.

Methods

Plasma samples were collected from patients undergoing lung resection preoperatively (day 0; n = 77) and postoperatively (day 1; n = 81). Blood bank plasma served as the control (n=24). Plasma lysis slope times were measured using the Lysis Timer, an automated assay that measures the rate of fibrin clot formation and subsequent tPA-stimulated clot breakdown in plasma. PAI-1 and tPA antigen levels were quantified and compared to fibrinolytic activity as measured on the lysis timer.

Results

A total of 84 patients were included. Preoperative (day 0) samples were available for 77 patients and postoperative (day 1) samples for 81 patients, and 24 blood bank plasma samples served as controls. Control samples demonstrated a median lysis slope time of 56.5 min. Patients undergoing lung resection showed significantly shorter plasma lysis slope times both preoperatively (median 33 min, p = 0.0051) and on postoperative day 1 (median 34 min, p = 0.0020) compared with controls, with no significant paired difference between day 0 and day 1 using the Wilcoxon signed-rank test (median day 0: 33 min; median day 1: 32 min; p = 0.7602). PAI-1 antigen levels were significantly elevated in patients both preoperatively and postoperatively compared with controls, with no significant paired difference between day 0 and day 1 (p = 0.4816). tPA antigen levels increased postoperatively and were significantly higher than both controls (p = 0.0009) and paired preoperative levels (p < 0.0001).

Conclusion

Lung cancer patients demonstrated shorter ex vivo plasma lysis slope times compared with controls, suggesting altered fibrinolytic potential under standardized assay conditions. These differences may contribute to postoperative complications, but the findings should be interpreted as assay-specific and require further study with larger longitudinal cohorts, medication-adjusted models, and additional in vivo coagulation/fibrinolysis markers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsFibrinolysisFibrin Clot Lysis TimeHumansFemaleMaleMiddle AgedAgedBiomarkersPlasminogen Activator Inhibitor 1

Stichwörter der Autor:innen

fibrinolysisglobal fibrinolysis capacity (GFC)lung cancerplasma lysis slope timeplasma lysis timerplasminogen activator inhibitor-1tissue plasminogen activator

Substanzen

BiomarkersPlasminogen Activator Inhibitor 1

Autor:innen und Institutionen

  • Department of Molecular Pharmacology and Neuroscience, Loyola University Stritch School of Medicine, Maywood, IL, USA.
  • Department of Molecular Pharmacology and Neuroscience, Loyola University Medical Center, Maywood, IL, USA.
  • Department of Molecular Pharmacology and Neuroscience, HYPHEN Biomed SAS, Paris, France.

ORCID-Profile: Prakasha Kempaiah, Debra Hoppensteadt, Jeanine Walenga, Jean Amiral, W Keith Jones, Jawed Fareed

Zitieren

APA

Vellanki, A., Kempaiah, P., Pohlman, A., Siddiqui, F., Jeske, W., Hoppensteadt, D., Walenga, J., Amiral, J., Jones, W. K., Fareed, J., & Abdelsattar, Z. (2026). Enhanced Fibrinolysis in Lung Cancer Patients: A Functional Assessment Using Lysis Slope Time and Fibrinolytic Biomarkers. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261475427

Vancouver

Vellanki A, Kempaiah P, Pohlman A, Siddiqui F, Jeske W, Hoppensteadt D, et al. Enhanced Fibrinolysis in Lung Cancer Patients: A Functional Assessment Using Lysis Slope Time and Fibrinolytic Biomarkers. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261475427

BibTeX
@article{Vellanki2026,
  author = {Vellanki, Anuha and Kempaiah, Prakasha and Pohlman, Alexander and Siddiqui, Fakiha and Jeske, Walter and Hoppensteadt, Debra and Walenga, Jeanine and Amiral, Jean and Jones, W Keith and Fareed, Jawed and Abdelsattar, Zaid},
  title = {Enhanced Fibrinolysis in Lung Cancer Patients: A Functional Assessment Using Lysis Slope Time and Fibrinolytic Biomarkers},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2026},
  volume = {32},
  doi = {10.1177/10760296261475427}
}
Kostenlos starten →